STSA-1002 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
STSA-1002 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed STSA-1002 in detail.
, Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults, Frontiers in Pharmacology, doi:10.3389/fphar.2026.1838620
STSA-1002 is a fully human monoclonal antibody targeting C5a, which plays a critical role in the pathogenesis of virus-induced acute respiratory distress syndrome ARDS (v-ARDS). We investigated safety, pharmacokinetics, pharmacodynamics, and anti-drug antibodies of increasing multiple intravenous doses of STSA-1002 in healthy adults. In vitro studies, STSA-1002 was a high-affinity, selective anti-human C5a monoclonal antibody blocking C5a-mediated reactive oxygen species (ROS) production. Building on the published preclinical results, a randomized, double-blind, placebo-controlled, dose-escalation study was done at a Phase I unit in China. A total of 60 adverse events (AEs) were reported. In the STSA-1002 group (n = 20), 47 AEs occurred in 18 participants (90.0%), corresponding to a mean of 2.6 AEs per participant. In the placebo group (n = 6), 13 AEs occurred in all 6 participants (100%), corresponding to a mean of 2.2 AEs per participant. Grade 2 or greater study drug-related adverse events included neutrophil count decreased, white blood cell count decreased, and aminotransferase increased. C max and AUC 0-t increased in an approximately dose-proportional manner. After the first dose, the mean concentration of free C5a in all dose groups was suppressed to below the lower limit of quantification. This suppression was maintained in all health volunteers until D42 (5 mg/kg) and D56 (10 mg/kg and 20 mg/kg) after multiple doses. Besides, STSA-1002 could downregulate the levels of myeloperoxidase (MPO), neutrophil elastase (NE), and proteinase 3 (PR3). Overall, multiple infusions of STSA-1002 up to 20 mg/kg appear to be safe and well tolerated in healthy participants in China. The safety, PK, and PD data support the continued evaluation of STSA-1002 in larger Phase II studies. Clinical Trial Registration: https://clinicaltrials.gov/ , ID NCT05497635.